Press Releases

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy. BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) — Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with second-line, relapsed or refractory large B-cell lymphoma (r/r LBCL) who were transplant-ineligible due to age, comorbidities, or other medical reasons. The primary analysis showed that zamto-cel demonstrated significant and clinically meaningful superiority over chemoimmunotherapy (R-GemOx) in transplant-ineligible patients who were at a high risk of rapid disease progression.1 This study population was characterized by older age and clinically high-risk disease features: the median age was 74 years, 57% of patients had a high International Prognostic Index (IPI≥ 3) and 67% presented with stage III/IV disease. Zamto-cel was well tolerated in this predominantly older and high-risk population.1 Dr. Peter Borchmann, Lead investigator of DALY 2-EU trial and Assistant Medical Director in the Department of Hematology and Oncology at the University Hospital of Cologne, Germany, said: “Zamto-cel demonstrated clinically meaningful and statistically significant superiority over R-GemOx in transplant-ineligible patients with high-risk disease, improving event-free survival while maintaining a favorable tolerability profile. These findings highlight the potential of zamto-cel as an important new treatment option for a clinically vulnerable patient population with

Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer Leave a reply Cochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26-metre electric TRAnsverse (“TRAnsverse 2600e”) tugs to be constructed in India for Svitzer’s global fleet renewal and growth plans.  Svitzer Nobbys TRAnsverse 3200 Pictured: A TRAnsverse 3200 tug. Svitzer’s agreement with Cochin Shipyard covers the related TRAnsverse 2600e electric tugs The agreement confirms a Letter of Intent signed in October 2025 at India Maritime Week and marks the move from intent to a contracted new build agreement. Under the agreement, CSL will build a minimum of four battery-electric TRAnsverse 2600e tugs for Svitzer, with an option for up to four additional vessels. The tugs will be constructed to Svitzer’s specifications at CSL’s facilities in Cochin to serve as global fleet renewal and advancement in operations worldwide. The vessels complement a wider newbuilding program of the TRAnsverse tug design, cementing Svitzer’s confidence in the vessel’s capabilities while also opening opportunities for future deployment in Indian ports and terminals. SVITZER Barrington Svitzer Barrington operating in Australia The deal brings together Svitzer’s global expertise in sustainable towage solutions with CSL’s proven shipbuilding capabilities, skilled workforce and local innovation. It supports India’s ambition to become a global maritime manufacturing and skills hub under Maritime India Vision 2030, Maritime Amrit Kaal Vision 2047 and the “Make in India” initiative. Kasper Karlsen COO Kasper Karlsen, Svitzer’s Chief Operating Officer The TRAnsverse 2600e tugs are the electric version of the next-generation tug design proving itself as the world’s most advanced and efficient tug. The ‘Swiss Army Knife’ of tugs: the TRAnsverse design can operate in complex and close-quarter operating contexts, with all ship types and sizes in challenging weather and

MRX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Marex Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action – MRX Leave a reply NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

MRX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Marex Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action – MRX Leave a reply NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.